Educational evidence summaries. No dosing, sourcing, or treatment instructions.
Articles centered on human clinical and pharmacology studies.
A clear comparison of CJC-1295 with DAC and the product commonly sold as CJC-1295 without DAC, including naming, half-life and evidence gaps.
Reviewed by Clinical Trial Review TeamWhy CJC-1295 and Ipamorelin are discussed together, what each receptor pathway does and why mechanism is not proof of clinical benefit.
Reviewed by Endocrine Evidence DeskAn evidence-based review of reactions reported in human research and FDA concerns involving compounded CJC-1295.
Reviewed by Clinical Trial Review TeamA claim-by-claim review separating measured GH and IGF-1 changes from unproven claims about fat loss, muscle growth, sleep, recovery and anti-aging.
Reviewed by Sports Integrity DeskA structured review of the landmark CJC-1295 healthy-adult trials, including endpoints, results, half-life and what the study cannot establish.
Reviewed by Endocrine Evidence DeskCompare two GHRH receptor agonists by molecular design, duration, human evidence, historical approval and current regulatory status.
Reviewed by Regulatory Review DeskA source-led review of human ipamorelin research, separating acute growth-hormone measurements from unproven clinical outcomes.
Reviewed by Clinical Trial Review TeamA structured comparison of GHRP-6 and ipamorelin covering receptor pharmacology, appetite observations and human evidence gaps.
Reviewed by Regulatory Review DeskAn evidence-led Hexarelin review focused on evidence checklist, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk